Background: Topical nasal steroids are commonly prescribed to patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) following endoscopic sinus surgery (ESS). They are found to be effective in improving symptoms and quality of life as well as reducing the incidence of nasal polyps recurrence. Objective: We sought to determine whether a higher concentration of topical nasal steroid spray is more effective than the standard nasal steroid spray in controlling symptoms and preventing recurrence of polyps in patients with CRSwNP who underwent ESS. Method: A double-blind randomized controlled trial was performed on patients with CRSwNP after ESS. Patients were randomized into 2 treatment groups: one received topical nasal dexamethasone 0.032% and the other, fluticasone proprionate. The 22-item Sino-Nasal Outcome Test (SNOT-22) and Lund-Kennedy nasal endoscopy scores were measured at the initiation of topical nasal steroid treatment and then at approximately 4-, 8-, and 12-week intervals. Results: Thirty-nine patients were enrolled in the study. Eighteen patients continued using the medications prescribed to them for the duration of the study. There were 8 patients in the dexamethasone group and 10 patients in the fluticasone group. Both groups saw significant improvements in postoperative SNOT-22 and Lund-Kenney scores over time. There was no significant difference in improvement between the groups. Conclusion: There is no significant increased benefit in using a higher dose nasal steroid spray compared to the standard dose nasal steroid spray after ESS.
Introduction
Chronic rhinosinusitis (CRS) is an inflammatory condition of the nose and paranasal sinuses and can be broadly classified into 2 subtypes depending on the presence or absence of nasal polyps. In chronic rhinosinusitis with nasal polyps (CRSwNP), treatment is targeted at reducing the inflammatory cycle within the nasal mucosa. Several randomized controlled studies have shown that CRSwNP responds excellently to both oral and topical corticosteroids. [1] [2] [3] Oral steroids tend to effectively reduce disease burden and improve patient symptoms. Prolonged use of oral steroids, however, is limited by the potential for adverse effects which include but are not limited to hyperglycemia, immunosuppression, gastric ulcers, osteoporosis, avascular necrosis adrenal suppression, and weight gain. 4 Topical nasal steroid sprays have been shown to have minimal systemic absorption and can be safely used as a long-term maintenance therapy in patients with CRSwNP. [5] [6] [7] [8] The mainstay anti-inflammatory medical treatment for CRSwNP is therefore topical nasal steroid sprays with a variety of the prescription formulations available including fluticasone, mometasone and budesonide. It is well known that topical corticosteroids reduce the rate of polyp recurrence, increase time to polyp recurrence, reduce the need for systemic steroids, and improve ostial patency and endoscopy scores post endoscopic sinus surgery (ESS). [9] [10] [11] [12] There is an increasing emphasis on the use of higher dose topical steroid therapy in patients CRSwNP, with the idea being that these formulations may be more beneficial than standard steroid sprays in decreasing disease burden and preventing polyp recurrence, especially in the postoperative period.
Although not FDA approved, doses nearly 100 times greater than those found in prescription nasal sprays have been used with promising results in CRSwNP patients. 3 Several formulations of high-dose topical steroid treatments have been used off label in CRSwNP including budesonide irrigations, prednisolone ophthalmic drops, and dexamethasone spray. 9, 13, 14 Although these higher potency off-label formulations provide increased concentration of local steroid therapy, there is concern for increased systemic absorption, with the potential for adrenal suppression and other long-term systemic steroid effects. Thus, it is important that if a high-dose topical steroid is used, its benefits must justify its risks. There are several case reports demonstrating intranasal dexamethasone drops causing iatrogenic Cushing's syndrome and adrenal insufficiency. [15] [16] [17] Furthermore, several studies have validated the short-term safety of budesonide nasal irrigations with one study noting concern with long-term use of the medication. [18] [19] [20] Few controlled studies have studied the benefits of high-dose topical steroid use, and none have specifically evaluated the efficacy of dexamethasone spray. 3, [21] [22] [23] Thus, we chose to perform a randomized, prospective, double-blinded study evaluating the effectiveness of high-dose dexamethasone spray compared to standard dose fluticasone spray in the postoperative period in CRSwNP. A recent safety analysis of dexamethasone spray failed to show an increase intraocular pressure but did find suppression of the hypothalamic-pituitary-adrenal axis in a small number of patients.
14 Thus, it is imperative to know if use of dexamethasone spray results in a clinically significant improvement over fluticasone which has a known safety profile in CRSwNP patients.
Materials and Methods
Adult patients who underwent endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis between 2013 and 2016 by 2 attending rhinologists were recruited. Nasal polyps were diagnosed in the office by nasal endoscopy and confirmed at the time of surgery. Patients were excluded from enrollment if they had a history of cystic fibrosis, immune deficiency, allergic fungal sinusitis, systemic vasculitis, granulomatous disease, ciliary dyskinesia, pregnancy, or allergy to steroids. Upon enrollment into the study, all patients signed informed consent. The study was approved by Loma Linda University's Institutional Review Board (approval number 5130043).
All patients underwent endoscopic sinus surgery for nasal polyposis. A standard 20 day systemic steroid taper was given to the patients, to start 10 days preoperatively. 4 patients were excluded due to contraindications to systemic steroids. At the first postoperative appointment, the patients were randomized to 1 of 2 groups: a group that received a prescription for fluticasone proprionate nasal spray (50 mcg per spray) or a group that received a prescription for 0.132% dexamethasone sodium phosphate nasal spray. Prescriptions were sent to the local compounding pharmacist in a numbered envelope thus blinding both the patient and the physician. Both nasal spray dispensers appeared identical (and the instructions for administration were identical). Patients were instructed to use 1 spray in each nostril twice daily. At the time of enrollment patients were asked to complete the 22-item Sino-Nasal-Outcome Test (SNOT-22), which was administered at 4, 8, and 12 weeks later. 24 At these same time points, patients underwent nasal endoscopy and were graded using the Lund-Kennedy endoscopic scoring system. 25 Both the patient and the supervising physician were unblinded after the week 12 visit. All patients were instructed to perform nasal saline irrigations postoperatively, but their adherence was not recorded.
Statistical Methods
Group differences were evaluated using pairwise comparison (ie, t test, Mann-Whitney test, and Fisher exact test). A fixed effect repeated measures analysis of variance with a first-order autoregressive (AR-1) covariance structure was utilized to determine whether there were group (fluticasone vs dexamethasone) differences in changes in SNOT-22 or Lund-Kennedy scores over time. SNOT-22 scores were log transformed before conducting analysis.
Results
Thirty-nine patients were enrolled in the study. Twentyone patients were lost to follow up, stopped using the nasal sprays, or switched medications during the study. There were 10 patients in the fluticasone group and 8 in the dexamethasone group who completed the study.
There were 10 patients in the fluticasone group and 11 in the dexamethasone group who did not complete the study. The average age at the time of surgery was 36 years old in the dexamethasone group and 52 years old in the fluticasone group (P ¼ .05, Table 1 ). However, age was not significantly associated with SNOT-22 or LundKennedy scores and was excluded from the final analyses. There was only 1 patient with aspirin sensitivity, and he was in the fluticasone group.
There was no significant difference found between the patients using fluticasone and those using dexamethasone in postoperative SNOT-22 (P ¼ .754) and LundKennedy scores (P ¼ .839) over time. Regardless of treatment type, there were significant reductions in postoperative SNOT-22 (P ¼ .003) and Lund-Kennedy scores over time (P ¼ .031) (Figures 1 and 2 ).
Discussion
Topical nasal steroids given postoperatively are thought to reduce polyp formation without the adverse effects of systemic corticosteroid treatment. Currently, there is a trend toward the use of higher dose topical steroid therapy in the postoperative period to further suppress mucosal inflammation, reduce the risk of ostial stenosis and the need for oral steroid rescue. Despite widespread use, there are few randomized controlled studies evaluating the effectiveness of these off-label, higher dose therapies in comparison to standard dose nasal steroid sprays. This randomized, prospective, double-blinded study showed no difference between high-dose dexamethasone spay compared to standard dose fluticasone spray after endoscopic sinus surgery in nasal polyp patients. Both groups showed improvement at the 4, 8, and 12 week mark in nasal endoscopy and SNOT 22 scores, consistent with normal healing after ESS.
Most studies on high-dose topical steroid therapy have looked at outcomes using budesonide irrigations. Penetration studies have clearly shown that large volume irrigation devices result in reliable distribution to the paranasal sinuses in the postoperative patient which could contribute to the improved efficacy seen with use of high-dose steroids delivered this way. 26 There is concern that traditional nasal sprays may not deliver the medication widely to the sinus cavities and may be more effectively distributed to the anterior nasal cavity. Distribution studies have suggested that majority of the spray remains in the nasal valve area with some distribution to the inferior turbinate and less so to the middle turbinate. 27 Nasal sprays fail to reliably reach the sinuses regardless of the surgical status. 28, 29 Conversely, There was no significant difference in patients with asthma, allergies, or prior sinus surgery between the dexamethasone and fluticasone groups. The average age at the time of surgery was 36 years in the dexamethasone group and 52 years in the fluticasone group (P ¼.05). Gender, age, asthma, allergies, and prior sinus surgery did not predict whether patients dropped out of the study. large volume irrigation devices result in reliable distribution to the paranasal sinuses especially after surgery. [30] [31] [32] However, given the nature of treatment delivery, a blinded study cannot be performed between irrigation and spray medication. Moreover, nasal saline irrigations, as a medium of medication delivery, have some undesirable features, such as uncontrolled variability and some of our patients have preferred nasal sprays to irrigations. We chose to compare a high-dose nasal steroid spray to the low dose nasal steroid spray to overcome these challenges. Unfortunately, the limitations in sinus penetration of nasal sprays may account for the lack of difference between the 2 groups in this study-that is, neither may have been very effective.
There were several other limitations to our study. The small sample size of the groups decreased the power of the data as many enrolled patients failed to consistently follow up until the end of the study. We also could have included preoperative and postoperative Lund-Mackay scores to shed additional light on the extent of sinus disease. Furthermore, the lack of a control group (no nasal steroids at all) prevents us determining if either nasal spray contributed to the improvements noted in the postoperative period.
Conclusion
There is no significant increased benefit in using a higher dose nasal steroid spray (dexamethasone) compared to standard dose nasal steroid spray (fluticasone) in the postoperative period, thereby not justifying the known increased systemic effects of the higher dose spray. 
